Oramed Pharmaceuticals (ORMP) Net Equity Issued and Repurchased (2010 - 2023)

Oramed Pharmaceuticals (ORMP) has 13 years of Net Equity Issued and Repurchased data on file, last reported at -$2000.0 in Q3 2023.

• Quarterly Net Equity Issued and Repurchased fell 100.05% year-over-year to -$2000.0 in Q3 2023, while the trailing twelve-month figure through Dec 2023 was $2.4 million (down 78.89% YoY) and the FY2023 annual result came in at $2.4 million, down 78.89% from the prior year.
• Net Equity Issued and Repurchased eased to -$2000.0 in Q3 2023, from $2.4 million in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $20.0 million in Q2 2020 to a low of -$7.6 million in Q2 2022.
• A 5-year average of $4.7 million and a median of $3.3 million in 2022 frame the typical range for Net Equity Issued and Repurchased.
• The widest YoY moves for Net Equity Issued and Repurchased: up 77.11% in 2023, down 100.05% in 2023.
• Tracing ORMP's Net Equity Issued and Repurchased over 5 years: stood at $1000.0 in 2019, then jumped by 1997800.0% to $20.0 million in 2020, then tumbled by 46.86% to $10.6 million in 2021, then slumped by 60.86% to $4.2 million in 2022, then sank by 100.05% to -$2000.0 in 2023.
• The last three Net Equity Issued and Repurchased figures came in at -$2000.0 (Q3 2023), $2.4 million (Q1 2023), and $4.2 million (Q4 2022), per Business Quant data.